Cyclacel Pharmaceuticals Net Income vs. Total Debt
| CYCCP Preferred Stock | USD 6.75 0.19 2.74% |
For Cyclacel Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cyclacel Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cyclacel Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cyclacel Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cyclacel Pharmaceuticals over time as well as its relative position and ranking within its peers.
Cyclacel |
Cyclacel Pharmaceuticals Total Debt vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cyclacel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cyclacel Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Cyclacel Pharmaceuticals is rated second in net income category among its peers. It is rated below average in total debt category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclacel Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Cyclacel Total Debt vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Cyclacel Pharmaceuticals |
| = | (18.89 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Cyclacel Pharmaceuticals |
| = | 113 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Cyclacel Total Debt vs Competition
Cyclacel Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 237.94 Million. Cyclacel Pharmaceuticals adds roughly 113,000 in total debt claiming only tiny portion of equities under Health Care industry.
Cyclacel Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cyclacel Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cyclacel Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Cyclacel Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Cyclacel Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Cyclacel Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cyclacel Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cyclacel Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cyclacel Pharmaceuticals' important profitability drivers and their relationship over time.
Use Cyclacel Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Cyclacel Pharmaceuticals Pair Trading
Cyclacel Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cyclacel Pharmaceuticals position
In addition to having Cyclacel Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Junk Bonds Funds Thematic Idea Now
Junk Bonds Funds
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cyclacel Preferred Stock Analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.